Imunon, Inc. quarterly report, Q3 FY2020

Business context and reporting period

This is Celsion Corporation’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2020, filed November 16, 2020. The request identifies Imunon, Inc., but the filing itself names Celsion Corporation (ticker CLSN); verify the issuer identity before relying on this summary.

Celsion was a clinical-stage oncology company developing ThermoDox, a heat-activated drug-delivery candidate, and GEN-1, a DNA-based immunotherapy for ovarian cancer. It reported no material product sales; licensing revenue came from amortizing a prior Hisun payment.

Financial results and liquidity

• At September 30, cash and cash equivalents were $18.34 million; current assets were $19.91 million, current liabilities $5.43 million, and working capital $14.48 million. The company held no available-for-sale debt securities at quarter-end.
• For the first nine months, operating cash outflow was $11.89 million, investing cash inflow $7.93 million, and financing cash inflow $15.42 million. Cash increased by $11.46 million from year-end 2019.
• Notes payable had a carrying value of approximately $5.04 million, after a $5 million principal repayment and related end-of-term charges in August. The amended Horizon loan is secured by substantially all company assets other than intellectual property, carries a minimum 9.625% interest rate, and includes liquidity and financing covenants.
• Management reported it believed available cash, potential New Jersey tax-loss sale proceeds, and remaining equity-facility capacity would fund operations through the end of 2021. This is an estimate dependent on assumptions, and additional capital may be needed.

Material changes versus prior comparable periods

• Third-quarter operating expenses fell 22% year over year, with R&D down 32%; nine-month operating expenses fell 13%. Management attributed lower R&D largely to reduced OPTIMA trial costs. G&A also declined over nine months, primarily from lower personnel costs and professional fees.
• Net loss increased year over year despite lower operating expenses: third-quarter loss rose to $8.07 million from $5.48 million, and nine-month loss to $18.47 million from $13.75 million. The 2020 periods included a $2.37 million non-cash impairment of the glioblastoma IPR&D asset and adverse non-cash remeasurement of the earn-out liability. In 2019, earn-out remeasurement had instead produced a gain over the nine-month period.
• Cash rose from $6.88 million at December 31, 2019 to $18.34 million at September 30, 2020, supported by equity issuance, including $20.25 million net proceeds from equity financing facilities during the first nine months. Shares outstanding increased substantially; the filing reports 36.16 million outstanding at September 30 and 37.42 million as of November 13.

Outlook, commentary, risks and unusual items

• ThermoDox/OPTIMA: After the second interim analysis, the independent monitoring committee recommended considering trial stoppage for futility. The reported futility statistic was 0.903 against a stopping boundary of 0.900; the two-sided p-value was 0.524, and no safety concerns were reported. Celsion chose to continue following overall survival and said further analyses would inform whether to proceed to a final analysis at 197 or more deaths, then expected around mid-2021. Management cited possible data immaturity, but trial success remained uncertain.
• GEN-1/OVATION 2: The first two patients were randomized into the Phase II portion in July 2020. The company anticipated completing enrollment of up to 118 Phase II patients in the third quarter of 2021. Earlier small-cohort findings cited in the filing are preliminary and are not a substitute for controlled trial results.
• Capital and dilution: Celsion repaid its May PPP loan in full after its June equity offering. It had remaining stated availability of $10.8 million under its JonesTrading sales agreement and $24.5 million under its Lincoln Park purchase agreement, subject to contractual conditions and share limits. Further equity financing could dilute existing holders. Horizon also required evidence by March 31, 2021 of at least $5 million in aggregate cash proceeds from specified funding sources after the amendment.
• Asset and earn-out items: The company wrote off the remaining approximately $2.4 million carrying value of its GBM IPR&D asset. The EGEN ovarian-cancer earn-out liability was valued at $7.12 million at quarter-end; changes in its fair value are non-cash but affect reported earnings. A milestone could trigger a payment choice of $7.0 million in cash or $12.4 million in cash, stock, or a combination, subject to the agreement.
• Other risks and contingencies: COVID-19 had not caused significant reported operating impacts through September 30, but could disrupt trials, enrollment, supply, regulatory activity, and access to capital. A shareholder action concerning the stock incentive plan was settled, including $187,500 of legal fees paid October 1, 2020. A separate securities class action filed October 29 alleged misleading statements about ThermoDox; the company said it would defend the case, and the possible loss could not be estimated. Nasdaq notified the company of a minimum-bid-price deficiency, with an initial compliance deadline of April 12, 2021.

Important facts for investors to verify

• Confirm that Celsion Corporation is the intended issuer for this 2020 filing, given the request’s Imunon, Inc. label.
• Review subsequent OPTIMA analyses and the eventual decision and outcome; the interim futility boundary was marginally crossed and management’s continuation rationale was not a demonstrated efficacy result.
• Assess cash burn, the basis for management’s end-of-2021 funding estimate, Horizon covenant compliance, and actual proceeds from tax-loss sales and equity facilities.
• Track potential dilution from outstanding warrants, options, incentive-plan shares, and further use of equity purchase agreements.
• Monitor the securities litigation, Nasdaq bid-price compliance, and any milestone payment obligations tied to the EGEN acquisition.